ERBA Diagnostics has something to crow about for 2013. Year-over-year, the Florida in vitro diagnostics outfit swung from a net loss to a small profit, aided, in part, by a surge in new revenue stemming from a 2012 acquisition. The company said it is eyeing more M&A deals in 2014.
Sequenom scored against Illumina's Verinata Health in a ruling at the U.S. Patent and Trademark Office involving noninvasive prenatal genetic diagnostic tech. Wasting no time, executives plan to use that decision as a weapon in an ongoing legal battle between the two California companies.
Despite heavy competition, GE Healthcare will forge ahead with its ongoing acquisition spree, division chairman and CEO John Dineen has said. Execs are continuing their search for more information technology and life sciences diagnostic deals to help enhance the company's edge.
Qiagen snatched up a biomarker from an Austrian research group that will aid in the development of a test designed to better diagnose rare blood disorders.
The University of California and a Chinese company will launch a high-end medical lab in Shanghai expected to handle molecular diagnostics and other tests for Chinese patients. They're billing the initiative as the first of its kind between a Chinese company and a U.S. academic medical center.
Philips Healthcare is touting some positive early results from a field study of its new hand-held blood test to spot patients at high risk for heart attacks or other "acute cardiac events."
Merck's venture capital arm is the lead investor in a $12 million financing round for promising molecular diagnostic outfit AdvanDx. Their target: hospital-acquired infections that are increasingly producing drug-resistant strains.
Exact Sciences President and CEO Kevin Conroy previously promised that 2014 will be all about getting the company's Cologuard colon cancer test to market. Now, the company will be armed with close to $120 million to get the job done.
We all know that med tech venture funding declined in 2013 in an ongoing trend in which those numbers have fallen for years. But we've seen some signs of VC life, and yes, even optimism, in 2014. Among the optimists: Barcelona venture capital firm Ysios Capital.
Seattle's Adaptive Biotechnologies has pulled in $105 million from Viking Global Investors to finish off combined Series C and D rounds. The cash infusion will expand the commercial reach of the company's immunosequencing tech to help diagnose and treat cancer, infectious diseases and autoimmune disorders.
Another newly discovered biomarker is now under consideration as a tool to help evaluate and treat disease. When the body expresses it, it appears to be tied to better survival chances in both non-small cell lung cancer and head and neck cancer.
Roche's Ventana Medical Systems will work with Denmark's Genmab to come up with a companion diagnostic test to be paired with a targeted anticancer drug now in development.
Foundation Medicine will develop a companion diagnostic test for use with a Clovis Oncology drug now in mid-stage clinical trials to treat patients with ovarian cancer.
Maryland's Personal Genome Diagnostics raised $2.8 million to help advance development of its cancer genome analysis technology. Separately, the company is launching its new METDetect Assay that helps spot alterations in the MET gene in circulating tumor DNA directly from a patient's blood.
Pfizer's venture investment arm is the lead backer in NeuMoDx Molecular's new $21 million Series B round. The Michigan startup attracted a new batch of financing designed to propel development of a highly efficient, low-cost molecular diagnostics platform and tests that can be run on it.
Two diagnostics companies hoping to improve the rate of early-stage colon cancer detection made it past an FDA panel of experts in late March with mixed results.
International researchers led by Michigan's Beaumont Health System discovered two biomarkers that helped predict resistance to radiation therapy for patient's with squamous cell cancer of the head and neck.
U.K. researchers have made advances developing a blood test that could screen for patients who have a genetic predisposition to obesity. Their work, published in the journal Diabetes, involves a team from the University of Southampton, University of Exeter Medical School and elsewhere.
A new diagnostic test screens for 5 protein biomarkers that can help differentiate septic shock patients at high or low risk for death. If further testing supports the initial findings, doctors will gain a tool to help them determine which patients need experimental therapies and which should get more traditional treatment.
California diagnostic maker Zyomyx pulled in $7.5 million from World Health Organization-hosted UNITAID to support commercialization of its MyT4 point-of-care CD4 test for HIV/AIDS in the developing world.